PT - JOURNAL ARTICLE AU - James D. Hocker AU - Olivier B. Poirion AU - Fugui Zhu AU - Justin Buchanan AU - Kai Zhang AU - Joshua Chiou AU - Tsui-Min Wang AU - Xiaomeng Hou AU - Yang E. Li AU - Yanxiao Zhang AU - Elie N. Farah AU - Allen Wang AU - Andrew D. McCulloch AU - Kyle J. Gaulton AU - Bing Ren AU - Neil C. Chi AU - Sebastian Preissl TI - Cardiac Cell Type-Specific Gene Regulatory Programs and Disease Risk Association AID - 10.1101/2020.09.11.291724 DP - 2020 Jan 01 TA - bioRxiv PG - 2020.09.11.291724 4099 - http://biorxiv.org/content/early/2020/09/12/2020.09.11.291724.short 4100 - http://biorxiv.org/content/early/2020/09/12/2020.09.11.291724.full AB - Background Cis-regulatory elements such as enhancers and promoters are crucial for directing gene expression in the human heart. Dysregulation of these elements can result in many cardiovascular diseases that are major leading causes of morbidity and mortality worldwide. In addition, genetic variants associated with cardiovascular disease risk are enriched within cis-regulatory elements. However, the location and activity of these cis-regulatory elements in individual cardiac cell types remains to be fully defined.Methods We performed single nucleus ATAC-seq and single nucleus RNA-seq to define a comprehensive catalogue of candidate cis-regulatory elements (cCREs) and gene expression patterns for the distinct cell types comprising each chamber of four non-failing human hearts. We used this catalogue to computationally deconvolute dynamic enhancers in failing hearts and to assign cardiovascular disease risk variants to cCREs in individual cardiac cell types. Finally, we applied reporter assays, genome editing and electrophysiogical measurements in in vitro differentiated human cardiomyocytes to validate the molecular mechanisms of cardiovascular disease risk variants.Results We defined >287,000 candidate cis-regulatory elements (cCREs) in human hearts at single-cell resolution, which notably revealed gene regulatory programs controlling specific cell types in a cardiac region/structure-dependent manner and during heart failure. We further report enrichment of cardiovascular disease risk variants in cCREs of distinct cardiac cell types, including a strong enrichment of atrial fibrillation variants in cardiomyocyte cCREs, and reveal 38 candidate causal atrial fibrillation variants localized to cardiomyocyte cCREs. Two such risk variants residing within a cardiomyocyte-specific cCRE at the KCNH2/HERG locus resulted in reduced enhancer activity compared to the non-risk allele. Finally, we found that deletion of the cCRE containing these variants decreased KCNH2 expression and prolonged action potential repolarization in an enhancer dosage-dependent manner.Conclusions This comprehensive atlas of human cardiac cCREs provides the foundation for not only illuminating cell type-specific gene regulatory programs controlling human hearts during health and disease, but also interpreting genetic risk loci for a wide spectrum of cardiovascular diseases.Competing Interest StatementB.R. is a shareholder and consultant of Arima Genomics, Inc. K.J.G is a consultant of Genentech, and shareholder in Vertex Pharmaceuticals. A.D.M. is a cofounder and Scientific Advisor to Insilicomed, Inc. and Vektor Medical, Inc. These relationships have been disclosed to and approved by the UCSD Independent Review Committee.